285 related articles for article (PubMed ID: 26272217)
21. Novel therapies in the treatment of multiple myeloma.
Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
[TBL] [Abstract][Full Text] [Related]
22. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
23. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Lee HS; Min CK
Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
[TBL] [Abstract][Full Text] [Related]
24. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
25. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
26. [First-line treatment of multiple myeloma].
Breitkreutz I; Raab M; Goldschmidt H
Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
[TBL] [Abstract][Full Text] [Related]
27. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
28. Maintenance treatment in multiple myeloma.
Harousseau JL
Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
[No Abstract] [Full Text] [Related]
29. [Multiple myeloma].
Špička I; Klánová M
Vnitr Lek; 2013 Jul; 59(7):627-30. PubMed ID: 23909272
[TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma: treatment evolution.
San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
[TBL] [Abstract][Full Text] [Related]
31. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli T; Palumbo A
Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
33. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies for the treatment of multiple myeloma.
Saini N; Mahindra A
Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
[TBL] [Abstract][Full Text] [Related]
35. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
36. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
37. New treatments in multiple myeloma: beyond optimal treatment.
Harousseau JL
Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
[No Abstract] [Full Text] [Related]
38. Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Migkou M; Gavriatopoulou M; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2018 Jun; 11(6):463-469. PubMed ID: 29788798
[TBL] [Abstract][Full Text] [Related]
39. Current and emerging treatments for multiple myeloma.
Schwartz RN; Vozniak M
J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
[TBL] [Abstract][Full Text] [Related]
40. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
